DEVELOPMENT OF ROS KINASE INHIBITORS - PHASE I SBIR TOPIC 255

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$203,208.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
N43CO201000106
Agency Tracking Number:
N43CO201000106
Solicitation Year:
2010
Solicitation Topic Code:
NCI
Solicitation Number:
PHS2010-1
Small Business Information
AUGUSTA PHARMACEUTICALS, INC.
58 OAK CLIFF RD, NEWTONVILLE, MA, 02460-
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
Y
Duns:
828453139
Principal Investigator:
Dorre Grueneberg
(713) 798-8167
Business Contact:
(617) 953-2641
Research Institution:
n/a
Abstract
The Augusta founding laboratories have used cutting edge genetic technologies and shRNA screening methodologies to uncover the ROS receptor tyrosine kinase as a cancer survival gene. Studies from other laboratories have drawn a clear link between ROS kinase activity and the development and/or progression of astrocytic tumors such as glioblastoma, a grade IV astrocytoma, based on genetic findings, gene expression data, and animal models. Taken together, these findings validate a scientific rationale that links ROS kinase activity to glioblastoma metabolism and its associated patient morbidity and mortality. The overall objective of this proposal is to develop small molecules that inhibit the kinase activity of the ROS receptor tyrosine kinase for the primary indication of human glioblastoma multiforme (GBM). The specific objective of this proposal is to further develop prototype compounds using standard medicinal chemistry practices to generate more potent ROS inhibitors as judged by two approaches: 1) inhibition of enzymatic activity in vitro

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government